Metformin Pharmacology
Mechanism of Action
Metformin works primarily by decreasing hepatic glucose production, reducing intestinal glucose absorption, and improving insulin sensitivity through increased peripheral glucose uptake and utilization 1. Unlike insulin secretagogues, metformin does not stimulate insulin secretion—fasting insulin levels may actually decrease while glucose control improves 1.
The drug acts at the mitochondrial level by inhibiting the respiratory chain complex I, which increases the AMP/ATP ratio and subsequently activates AMP-activated protein kinase (AMPK) 2. Additional proposed mechanisms include binding to presenilin enhancer 2, increasing GLP-1 release, and modifying microRNA expression 2.
Pharmacokinetics
Absorption
- Bioavailability: 50-60% under fasting conditions 1
- Time to peak: Immediate-release reaches steady state in 24-48 hours; extended-release achieves Cmax at median 7 hours (range 4-8 hours) 1
- Dose proportionality: Lacks dose proportionality with increasing doses due to decreased absorption, not altered elimination 1
- Food effect: Food decreases Cmax by ~40%, AUC by 25%, and delays Tmax by 35 minutes 1
Distribution
- Volume of distribution: 654 ± 358 L following single 850 mg dose 1
- Negligibly bound to plasma proteins 1
- Partitions into erythrocytes 1
Metabolism & Elimination
- No hepatic metabolism—excreted unchanged in urine 1
- Renal clearance is the primary elimination route via glomerular filtration and tubular secretion using cationic transporters (OCT/MATE) 1, 2
- Half-life: approximately 5 hours 3
Dosing Guidelines
Standard Dosing
- Usual effective dose: 1,500-2,500 mg/day in divided doses 3
- Immediate-release: Twice-daily dosing 4
- Extended-release: Once-daily dosing 4
- Titration strategy: Gradual dose escalation to minimize gastrointestinal side effects 4
Renal Dose Adjustments
- eGFR ≥30 mL/min/1.73 m²: May be safely used 4
- eGFR 30-45 mL/min/1.73 m²: Increased risk of periodic decreases to ≤30, requiring dose adjustment and monitoring 4, 5
- eGFR <30 mL/min/1.73 m²: Contraindicated 1, 5
Contraindications
Metformin is absolutely contraindicated in 1:
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Hypersensitivity to metformin
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Additional contraindications from clinical practice 5:
- Concurrent active or progressive severe liver disease
- Active alcohol abuse
- Unstable or acute heart failure
- Hypoperfusion and hemodynamic instability
- Past history of lactic acidosis
Contrast Media Considerations
New recommendations indicate metformin must be stopped only when eGFR is <45 mL/min/1.73 m² before iodine contrast administration, as the risk of lactic acidosis is very low 6.
Adverse Effects
Common (Gastrointestinal)
- Most frequent: Bloating, abdominal discomfort, diarrhea 4
- Usually mild and transient 5
- Mitigation strategies: Gradual dose titration and/or extended-release formulation 4
- Women experience GI symptoms more frequently than men 7
Metabolic
- Vitamin B12 deficiency: Positive correlation with duration and daily dose of metformin 4, 5, 7
- May worsen symptoms of neuropathy 4
- Recommendation: Periodic testing of vitamin B12 levels 4
Rare but Serious
- Lactic acidosis: Very rare occurrence (metformin-associated lactic acidosis, MALA) 4, 5
- Primarily occurs when eGFR <30 mL/min/1.73 m² 4
- Associated with very high circulating levels from overdose or acute kidney injury 4
- Risk increases with renal impairment, severe liver disease, alcohol abuse, and conditions causing hypoperfusion 5
Clinical Positioning
Metformin remains the commonly used first-line medication for type 2 diabetes when no additional considerations beyond glucose lowering exist 4. It is effective and safe, inexpensive and widely available, and reduces risks of microvascular complications, cardiovascular events, and death 4.
Key Advantages
- Weight neutral (compared to sulfonylureas) 4
- No hypoglycemia risk 4
- Reduces cardiovascular mortality compared to sulfonylureas 4
- More effective than DPP-4 inhibitors in lowering A1C and weight as monotherapy 4
- May favorably influence lipid profiles 3
Important Caveats
For patients with established atherosclerotic cardiovascular disease where major adverse cardiovascular events (MACE) are the primary concern, GLP-1 receptor agonists have the greatest level of evidence for MACE benefit 8. The positioning of metformin as universal first-line therapy is evolving as diabetes management increasingly prioritizes cardiovascular and renal outcomes alongside glycemic control.